Primary Mold-Active Antifungal Prophylaxis Decreases the Need for Chest Computed Tomography Scans in Patients with

Nihal Karadaş1, Hamiyet Hekimci Özdemir1, Yeşer Yilmaz2

  • 1Ege University Faculty of Medicine, Children's Hospital, Department of Pediatric Hematology, IZMIR, Bornova, Turkey.

Insights

Antifungal prophylaxis (AFP) with voriconazole significantly reduced the need for computed tomography (cCT) chest scans in children with acute lymphoblastic leukemia (ALL). This approach also lowered rates of invasive fungal infections and mortality.

Area of Science:

  • Pediatric Oncology
  • Infectious Diseases
  • Radiology

Background:

  • Current guidelines recommend chest computed tomography (cCT) scans for children with leukemia to detect invasive fungal infections (IFIs).
  • cCT scans expose high-risk pediatric patients to radiation, increasing the risk of secondary cancers.

Purpose of the Study:

  • To evaluate the impact of antifungal prophylaxis (AFP) with voriconazole (VCZ) on the necessity of cCT scans in children with acute lymphoblastic leukemia (ALL).
  • To assess if AFP can mitigate the need for radiation exposure from cCT scans in this vulnerable population.

Main Methods:

  • Retrospective analysis of electronic health records for children diagnosed with ALL before February 2013.
  • Comparison of two groups: those who received mold-active AFP (voriconazole) versus those who did not (NoP group).
  • Evaluation of cCT scan utilization, proven-probable IFIs, and relapse-mortality rates between the groups.

Main Results:

  • The AFP group required significantly fewer cCT scans (64 scans in 52 children) compared to the NoP group (128 scans in 62 children).
  • A lower percentage of patients in the AFP group needed at least one cCT scan.
  • The NoP group exhibited higher rates of proven-probable IFIs and relapse-mortality compared to the AFP group.

Conclusions:

  • Mold-active antifungal prophylaxis, specifically with voriconazole, significantly decreases the requirement for chest cCT scans in children undergoing chemotherapy for ALL.
  • AFP serves as an effective strategy to reduce radiation exposure in pediatric ALL patients while managing IFI risk.